ライフサイエンスコーパス: fasudil

1 an (fasudil and ripasudil) and one in China (fasudil).

2 nged with HDM extracts and then treated with fasudil.

3 icial effects of ANG-(1-7) were prevented by fasudil.

4 y pretreatment with the rho kinase inhibitor fasudil.

5 ogical intervention with the ROCK inhibitor, fasudil.

6 neurons or treatment with the ROCK inhibitor fasudil.

7 udies revealed that the Rho-kinase inhibitor fasudil (1 micromol/L) significantly blunted artery cont

8 te experiments, diabetic db/db mice received fasudil (10 mg x kg(-) x day(-) i.p.) or simvastatin (40

9 als were randomly assigned to treatment with fasudil (136 or 213 mg x kg(-1) x d(-1) in drinking wate

10 ome mice also were given the ROCK1 inhibitor fasudil; 2 weeks later, serum EVs were isolated and char

11 Fasudil, a clinically approved ROCK inhibitor, suppresse

12 that was inhibited by treating animals with fasudil, a pharmacologic ROCK inhibitor, and that both R

13 The i.t. administration of fasudil, a Rho kinase inhibitor, reversed the hypertensi

14 In this study, we tested the hypothesis that fasudil, a Rho-kinase inhibitor, could attenuate Ang II-

15 Similarly, fasudil, a ROCK inhibitor used clinically to treat cereb

16 creased vascular leak in vivo, reversible by fasudil, a ROCK inhibitor.

17 downstream from RhoA, we treated cells with fasudil, a selective Rho kinase inhibitor, and found tha

18 We examined whether fasudil, a selective Rho-A/Rho kinase inhibitor, affects

19 Fasudil, a selective Rho-A/Rho kinase inhibitor, has bee

20 Recent studies have shown that fasudil, a selective ROCK inhibitor, may play a pivotal

21 Compared to intravenous (IV) fasudil, a ~10 fold increase in the terminal plasma half

22 Fasudil administration significantly decreased the numbe

23 terestingly, blood glucose was unaffected by fasudil administration.

24 Fasudil also blocks habitual responding for cocaine, an

25 Fasudil also decreased the expression and phosphorylatio

26 Despite more occlusive vascular lesions, fasudil also markedly reduced right ventricular systolic

27 Fasudil also reduced mucous secretion and MUC5AC express

28 The ROCK inhibitor, fasudil, also reduced airway responsiveness in OVA-chall

29 ought to evaluate the efficacy and safety of fasudil, an orally available rho kinase inhibitor, in pa

30 t not systemic, effects of the vasodilators, fasudil and imatinib, in PAH rats.

31 e functionalization of the medicinal agents, fasudil and milrinone.

32 ave been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil).

33 e presence of Rho-effector kinase inhibitors Fasudil and Y-27632, but ATP-induced IL-1 beta release w

34 Inhaled fasudil, another Rho kinase inhibitor, caused selective

35 However, fasudil as a monotherapy did not affect behavioral funct

36 mm ST-segment depression was increased with fasudil at both peak and trough compared with placebo (1

37 demonstrate that inhibition of Rho-kinase by fasudil attenuated Ang II-induced AAA through inhibition

38 Inhibition of Rho-kinase (ROCK) with fasudil blocked HG-induced podocyte MP formation.

39 human CCM endothelium, and they suggest that fasudil could ameliorate both CCM disease and vascular l

40 At the higher dose, fasudil decreased AAA by 45% while significantly inhibit

41 FSD-C10, a Fasudil derivative, was shown to reduce severity of expe

42 Fasudil did not affect heart rate or blood pressure, and

43 Further investigation of fasudil doses >80 mg three times daily is indicated.

44 Fasudil down-regulated the levels of IL-17, IL-4 and IL-

45 Treatment with fasudil during the postinflammatory fibrotic phase of lu

46 Co-administration of BI-2536 and fasudil either in the LSL-KRAS(G12D) mouse model or in a

47 We find that the inhibitor fasudil enhances action-outcome memory, resulting in goa

48 entrapment efficiency of optimized liposomal fasudil formulations was between 68.1+/-0.8% and 73.6+/-

49 tion of an investigational anti-PAH molecule fasudil (HA-1077), a Rho-kinase inhibitor, into liposoma

50 As fasudil has been safely used in humans, our results sugg

51 petitive small molecule inhibitors (Y-27632, fasudil, hydroxyfasudil, and H-1152P).

52 Fasudil improved Seattle Angina Questionnaire scores.

53 independent vasodilation was not affected by fasudil in either CAD or healthy subjects.

54 Fasudil increased endothelium-dependent vasodilation in

55 transduction pathway with the ROCK inhibitor fasudil induced myofibroblast apoptosis through a mechan

56 bition of the spatial rescue of alpha2C-ARs, fasudil inhibited alpha2-AR-mediated mobilization of cal

57 Fasudil inhibited HDM extract-induced MUC5AC expression,

58 eased in lungs from both groups of rats, and fasudil (intravenous) reversed the increased phosphoryla

59 roof-of-principle that aerosolized liposomal fasudil is a feasible option for a non-invasive, control

60 Hydroxyfasudil, a metabolite of fasudil, may be selective for ROCK over PKA through a re

61 fter intratracheal instillation of liposomal fasudil, mean pulmonary arterial pressure (MPAP) was red

62 Fasudil or matching placebo was force-titrated from 20 m

63 ucible exercise times were randomized 1:1 to fasudil or placebo.

64 prevented by inhibition of Rho kinase, using fasudil or RNA interference.

65 lockade of the RhoA/ROCK pathway with either fasudil or simvastatin would ameliorate progression of d

66 n A receptor blocker BQ123 and completely by fasudil or Y-27632.

67 ssigned to receive the Rho kinase inhibitor, fasudil, or placebo for 1 month each in a double-blind c

68 ndicate that the Rho-A/Rho kinase inhibitor, fasudil, plays a negative regulatory role in allergen-in

69 ation of the Rho-associated kinase inhibitor fasudil prevented renal fibrosis and restored expression

70 activity, using the clinically approved drug fasudil, prevented dendritic network disorganization, me

71 Fasudil reduced Rho kinase activity by 59+/-18% in CAD s

72 , non-placebo-controlled trials suggest that fasudil reduces myocardial ischemia in patients with sta

73 thelium-dependent vasodilation achieved with fasudil relative to placebo was inversely proportional t

74 , treatment with the approved ROCK inhibitor fasudil resulted in increased apoptosis and decreased vi

75 Administration of the ROCK1 inhibitor fasudil to mice with NASH reduced serum levels of EVs; t

76 Fasudil transiently reduces prelimbic cortical dendritic

77 The fasudil-treated mice exhibited a significant reduction i

78 Fasudil treatment resulted in a dose-dependent reduction

79 hallenged with ovalbumin (OVA) followed with fasudil treatment.

80 Fasudil up to 80 mg three times daily significantly incr

81 as numerically greater in patients receiving fasudil versus those receiving placebo.

82 The t1/2 of IV fasudil was 0.39+/-0.12 h.

83 When fasudil was administered 30 minutes before simvastatin (

84 plasma half-life was observed when liposomal fasudil was administered as aerosols.

85 In 1995 fasudil was approved for the treatment of cerebral vasos

86 epared by hydration and extrusion method and fasudil was loaded by ammonium sulfate-induced transmemb

87 In the early group, intravenous fasudil was more effective than intravenous bradykinin,

88 randomized trial, the efficacy and safety of fasudil were evaluated in stable angina patients.

89 ffect of RhoA/ROCK inhibitors (C3-exoenzmye, fasudil, Y-27632, ibuprofen, siRhoA, and p21) in experim

90 Inhibition of Rho kinase (fasudil, Y27632 or H-1152) did not affect constriction o